Engels N Obi
Overview
Explore the profile of Engels N Obi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soriano A, Paterson D, Thalhalmmer F, Kluge S, Viale P, Akrich B, et al.
Diagn Microbiol Infect Dis
. 2025 Feb;
111(4):116737.
PMID: 39955850
Background: Ceftolozane/tazobactam (C/T) real-world use was examined in a global population of critical care patients treated in intensive care unit settings. Methods: The Study of Prescribing patterns and Effectiveness of...
2.
Soriano A, Paterson D, Thalhammer F, Kluge S, Viale P, Watanabe A, et al.
J Glob Antimicrob Resist
. 2025 Jan;
41:272-279.
PMID: 39864656
Objectives: Antibacterial-resistant gram-negative hospital-acquired infections result in significant morbidity and mortality. In clinical trials, ceftolozane/tazobactam (C/T) has been effective against these infections; however, real-world findings are limited. Methods: SPECTRA was...
3.
Dubberke E, Li Q, Obi E, Turzhitsky V, Siddiqui F, Nathanson B
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae524.
PMID: 39355263
Background: The 2021 update to the Infectious Diseases Society of America infection (CDI) guidelines recommended fidaxomicin as the preferred treatment over vancomycin for patients with initial and recurrent CDI. Few...
4.
Lodise T, Obi E, Watanabe A, Yucel E, Min J, Nathanson B
J Antimicrob Chemother
. 2024 Sep;
79(11):2954-2964.
PMID: 39258877
Background: Ceftolozane/tazobactam and ceftazidime/avibactam are commonly used in patients with MDR-Pseudomonas aeruginosa (PSA) pneumonia (PNA). This study compared outcomes between non-COVID-19 hospitalized patients with MDR-PSA PNA who received ceftolozane/tazobactam or...
5.
Lodise T, Yucel E, Obi E, Watanabe A, Nathanson B
J Antimicrob Chemother
. 2023 Nov;
79(1):82-95.
PMID: 37962080
Background: Limited comparative data exist on acute kidney injury (AKI) risk and AKI-associated outcomes in hospitalized patients with carbapenem-resistant Gram-negative infections (CR-GNIs) treated with a newer β-lactam/β-lactam-β-lactamase inhibitor (BL/BL-BLI)-, polymyxin...
6.
Deshpande A, Chen Y, Boye-Codjoe E, Obi E
Open Forum Infect Dis
. 2022 Dec;
9(12):ofac622.
PMID: 36519119
Background: In October 2017, the single International Classification of Diseases, Tenth Revision (ICD-10), code for infection (CDI), A04.7, was replaced with 2 codes delineating "recurrent CDI" (rCDI; A04.71) and "nonrecurrent...
7.
McDaniel L, White M, Obi E, Kohinke R, Lockhart E, Chipriano D, et al.
Infect Dis Ther
. 2022 Dec;
12(1):109-110.
PMID: 36459384
No abstract available.
8.
Francisco D, Zhang L, Jiang Y, Olvera A, Adachi J, Yepez Guevara E, et al.
Infect Dis Ther
. 2022 Nov;
12(1):209-225.
PMID: 36443547
Introduction: Antibiotic use is a risk factor for Clostridioides difficile infection (CDI). Few studies have correlated use of prior antibiotic classes with CDI, microbiome composition, and disease severity in patients...
9.
Dubberke E, Puckett J, Obi E, Kamal-Bahl S, Desai K, Stuart B, et al.
Open Forum Infect Dis
. 2022 Oct;
9(10):ofac435.
PMID: 36267250
Background: The 2017 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) infection (CDI) guideline update recommended treatment with fidaxomicin or vancomycin for CDI. We aimed to examine...
10.
Schroeder C, Hengel R, Nathan R, Ritter T, Obi E, Lancaster C, et al.
Anaerobe
. 2022 Aug;
77:102617.
PMID: 35940371
Objectives: Patients with Clostridioides difficile infection (CDI) who receive treatment at outpatient infusion centers (OICs) pose a risk for spore transmission. We investigated C. difficile contamination in the environment of...